Harold Schaaff
@Soleus Capital Management, L.p.
Latest period2024 - Q3ReportedManaged Assets$1.291BTotal holdings87
Assets growth rate13.9%Assets growth rate (2-Q avg)-0.97%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Soleus Capital Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 87 positions.
Assets under management
The assets under management (AUM) of Soleus Capital Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.291B in assets, with a quarterly growth rate of 13.9% and a 2-quarter average growth rate of -0.97%. The portfolio is managed by Harold Schaaff, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
RIGLRigel Pharmaceuticals Inc
| 1.18% | $15.125M 934,788 shares@ $16.19 avg price | Decreased -10.43% |
PRAXPraxis Precision Medicines I
| 1.16% | $14.926M 259,398 shares@ $57.55 avg price | Decreased -51.33% |
CGONCg Oncology Inc
| 1% | $12.85M 340,585 shares@ $37.73 avg price | Decreased -19.78% |
ENTAEnanta Pharmaceuticals Inc
| 0.64% | $8.138M 785,546 shares@ $10.37 avg price | Decreased -1.75% |
KIDSOrthopediatrics Corp
| 0.61% | $7.833M 288,945 shares@ $27.12 avg price | Decreased -6.64% |
ACLXArcellx Inc
| 0.61% | $7.769M 93,031 shares@ $83.52 avg price | Decreased -45.51% |
NUVLNuvalent Inc
| 0.59% | $7.607M 74,357 shares@ $102.3 avg price | Decreased -56.71% |
BDSXBiodesix Inc
| 0.56% | $7.188M 4.038M shares@ $1.79 avg price | Decreased -33.93% |
ELVNEnliven Therapeutics Inc
| 0.48% | $6.122M 239,705 shares@ $25.55 avg price | Decreased -68.83% |
APLTApplied Therapeutics Inc
| 0.45% | $5.787M 680,784 shares@ $8.5 avg price | Decreased -46.38% |